CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Jul. 03, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 1,780	$ 1,944
Short-term investments		31,524	29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$461; 2021—$492		15,155	11,479
Inventories	[1]	10,454	9,059
Current tax assets		2,583	4,266
Other current assets		5,970	3,820
Total current assets		67,466	59,693
Equity-method investments		14,799	16,472
Long-term investments		4,163	5,054
Property, plant and equipment, less accumulated depreciation: 2022—$14,969; 2021—$15,074		15,244	14,882
Identifiable intangible assets	[2],[3]	29,065	25,146
Goodwill	[4]	49,891	49,208
Noncurrent deferred tax assets and other noncurrent tax assets		7,002	3,341
Other noncurrent assets		7,659	7,679
Total assets		195,290	181,476
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2022—$1,276; 2021—$1,636		5,990	2,241
Trade accounts payable		6,208	5,578
Dividends payable		2,245	2,249
Income taxes payable		3,350	1,266
Accrued compensation and related items		1,997	3,332
Deferred revenues		3,804	3,067
Other current liabilities		23,816	24,939
Total current liabilities		47,410	42,671
Long-term debt		34,294	36,195
Pension benefit obligations		3,030	3,489
Postretirement benefit obligations		227	235
Noncurrent deferred tax liabilities		558	349
Other taxes payable		10,990	11,331
Other noncurrent liabilities		11,311	9,743
Total liabilities		107,821	104,013
Commitments and Contingencies
Common stock		476	473
Additional paid-in capital		91,183	90,591
Treasury stock		(113,939)	(111,361)
Retained earnings		116,608	103,394
Accumulated other comprehensive loss		(7,119)	(5,897)
Total Pfizer Inc. shareholders’ equity		87,208	77,201
Equity attributable to noncontrolling interests		261	262
Total equity		87,469	77,462
Total liabilities and equity		$ 195,290	$ 181,476

[1] The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, and increases for certain products due to network strategy and supply recovery, partially offset by decreases due to market demand.

[2] The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A.

[3] The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.

[4] All goodwill is assigned within the Biopharma reportable segment.